Welcome to our dedicated page for BioSig Technologies news (Ticker: BSGM), a resource for investors and traders seeking the latest updates and insights on BioSig Technologies stock.
The BSGM news archive on Stock Titan covers the corporate evolution of BioSig Technologies, Inc. into Streamex Corp., a Nasdaq-listed company now trading under the symbol STEX. Company press releases and SEC-referenced announcements document the merger between BioSig Technologies and Streamex Exchange Corporation, the subsequent name change to Streamex Corp., and the ticker change from BSGM to STEX on the Nasdaq Capital Market.
Earlier news items in this history describe BioSig’s activities as a medical device technology company focused on the PURE EP™ Platform for electrophysiology procedures. More recent releases highlight the company’s strategic pivot toward real-world asset tokenization and gold-focused financial infrastructure through Streamex. Disclosures discuss Streamex as a gold tokenization and gold treasury business building institutional-grade infrastructure to bring the gold and commodities markets on chain.
Readers can find coverage of key developments such as the closing of the merger with Streamex Exchange Corporation, public offerings of common stock to purchase gold bullion under an investment policy, and a tokenized yield partnership agreement related to precious-metal lease and bond programs. News items also address plans to operate as a regulated participant in tokenized real-world asset markets, including engaging a specialist firm to manage the acquisition of a FINRA and SEC-registered broker-dealer.
For anyone tracking the company’s journey from its BSGM days to its current STEX identity, this news page provides a chronological view of material announcements, strategic partnerships, capital markets activity, and governance changes that define the transition from a medical device issuer to a gold tokenization and RWA-focused enterprise.
BioSig Technologies (NASDAQ: BSGM) has signed an agreement with Medical City North Hills in Texas for the clinical evaluation of its PURE EP technology aimed at enhancing arrhythmia care. This partnership adds to BioSig's installations in Texas, alongside facilities like Houston Methodist Hospital. With over 400 EP labs, Texas represents a key market for BioSig’s growth strategy. The FDA-cleared PURE EP device has already facilitated over 1,000 patient cases across multiple sites, highlighting its potential to address the growing prevalence of cardiac arrhythmias.
BioSig Technologies, Inc. (BSGM) has announced a conference call on July 26, 2021, to discuss findings from its PURE EP 2.0 clinical trial, which involved 51 patients across three leading medical centers. The PURE EP™ System aims to enhance procedural efficiency in electrophysiology by improving signal fidelity for cardiac ablation procedures. More than 50 physicians have utilized the system in over 1000 patient cases. The trial's enrollments were completed in April 2021, and further presentations will take place at upcoming medical conventions.
BioSig Technologies, Inc. (Nasdaq: BSGM) announced the completion of an underwritten public offering of 2,500,000 shares at $4.00 per share, raising gross proceeds of $10 million. The funds will support the commercialization of the PURE EP™ System, further research and development, and general corporate needs. Laidlaw & Company (UK) Ltd. acted as the sole book-running manager for this offering, which follows a previously effective shelf registration statement. The prospectus relevant to the offering is available on the SEC's website.
BioSig Technologies has successfully installed its PURE EP(tm) system at New York Presbyterian, a leading healthcare institution in NYC, enhancing arrhythmia care. The FDA-cleared device aims to improve procedural efficiency in electrophysiology, supported by over 1,000 patient cases across various clinical sites. With cardiac arrhythmia affecting 33 million globally, the market for such innovations is significant. This launch is part of BioSig’s strategic rollout, targeting key areas in the Northeast for better patient outcomes.
BioSig Technologies, Inc. (Nasdaq: BSGM) announced the pricing of a public offering of 2,500,000 shares of its common stock at $4.00 per share, expected to generate approximately $10 million in gross proceeds. If the underwriter exercises its option for an additional 15%, proceeds may reach $11.5 million. The offering is scheduled to close on July 7, 2021. Funds will support commercialization of the PURE EP™ System and ongoing R&D activities. Laidlaw & Company acts as the sole book-running manager.
BioSig Technologies (Nasdaq: BSGM) announced a public offering of its common stock, with the potential for an additional 15% of shares. The move aims to fund commercialization of the PURE EP™ System, support organizational growth, and continue research and development. The offering is contingent on market conditions, with no certainty regarding completion or terms. The relevant shelf registration statement was filed with the SEC and is effective as of January 12, 2021.
BioSig Technologies, Inc. (NASDAQ: BSGM) has surpassed its initial target of conducting 1000 patient cases with its PURE EP™ System, achieving this milestone at nine installation sites. The Company has raised its procedural volume goal to at least 1500 by the end of 2021, driven by increased technology adoption in electrophysiology. BioSig's expansion includes enhancing its commercial team and targeting key regions: the Northeast, Texas, and Florida. The ongoing rise in technology use signals a recovery from pandemic-related challenges, potentially positioning BioSig for strong performance in the latter half of 2021.
BioSig Technologies (Nasdaq: BSGM) will present its latest software for arrhythmia care at the 2021 Stanford Biodesign New Arrhythmia Technologies Retreat on July 27. The presentation will showcase advancements in the PURE EP(tm) System, designed to improve signal fidelity and procedural efficiency in electrophysiology. Since the targeted commercial launch in 2020, 55 physicians have conducted over 950 patient cases using the system, which has received FDA 510(k) clearance. Atrial fibrillation affects over 33 million globally, highlighting the software's potential impact in addressing this growing healthcare challenge.
BioSig Technologies (NASDAQ: BSGM) announced that data from its PURE EP(tm) System will be presented at the Heart Rhythm 2021 convention in Boston from July 28-31, 2021. Two significant presentations include "Post-Ablation Bipolar Voltage By PURE EP(tm) As a Marker Of Transmural Lesion" and "Atrial Unipolar Electrogram Filtering to Better Delineate EGM Amplitude During Radiofrequency Ablation." The PURE EP(tm) System has received FDA 510(k) clearance, with over 950 patient cases completed across multiple clinical sites. The company aims to enhance procedural efficiency in electrophysiology.
BioSig Technologies (Nasdaq: BSGM) announced its participation in the Heart Rhythm 2021 convention, scheduled for July 28-31, 2021, in Boston, MA. The company will showcase its PURE EP(tm) System, a cutting-edge signal processing platform designed for cardiac arrhythmia care. In April 2021, BioSig completed the enrollment of 51 patients for a clinical trial on various arrhythmia cases, including atrial fibrillation. The PURE EP(tm) System has received FDA 510(k) clearance and has been utilized in over 940 patient cases by 52 physicians across multiple sites.